Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
Related Questions
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
How do you differentiate demoralization from depression during cancer treatment?
What are your top takeaways in Classical Hematology from ASH 2024?
Is there specific data on using luspatercept for sickle beta+ thalassemia with transfusion-dependent anemia?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
What are some of the medical management strategies for pediatric extracranial AVMs?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Based on the FIREFLY-1 data, would you consider using tovorafenib monotherapy front-line in pediatric patients who have low grade gliomas that are only amenable to subtotal resection or are unresectable?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
